Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COINED: Nalmefene vs Naloxone for Opioid Overdose
NCT05808881Phase 4Withdrawn
- Sponsor
- Purdue Pharma
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of nalmefene in opioid overdose (2 arms), sponsored by Purdue Pharma. Primary endpoint: Reversal of Respiratory Depression at 3 hours. Planned start Jun 2023; status: withdrawn.
02
Drugs
nalmefene
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT05808881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808881.